Related Experiment Video
Updated: Apr 29, 2026

Colletotrichum fioriniae Development in Water and Chloroform-based Blueberry and Cranberry Floral Extracts
Published on: April 12, 2019
Proanthocyanin content in cranberry CE medicinal products
Sigrun Chrubasik-Hausmann1, Christian Vlachojannis, Benno F Zimmermann
1Institute of Forensic Medicine, University of Freiburg, Albertstr. 9, 79104, Freiburg, Germany.
Cranberry CE products often contain less proanthocyanin (PAC) than declared. Many products provide inadequate dosages, failing to deliver promised health benefits, necessitating better regulatory control.
Area of Science:
- Pharmacognosy
- Analytical Chemistry
- Regulatory Science
Background:
- CE marking indicates compliance with European directives for certain products.
- Cranberry products are often marketed for health benefits attributed to proanthocyanins (PACs).
- Regulation of CE-marked medicinal products differs from those overseen by the European Medicines Agency.
Purpose of the Study:
- To quantify the proanthocyanin (PAC) content in four cranberry CE-marked products.
- To compare manufacturer-recommended daily dosages with literature-based benchmark doses for efficacy.
- To assess the adequacy of PAC content in CE-marked cranberry products for claimed health benefits.
Main Methods:
- Quantitative analysis of PAC content using a photometric DMAC assay (4-dimethylamino-cinnamic-aldehyde).
- High-performance liquid chromatography (HPLC) assay for PAC quantification.
- Comparison of product-specific PAC content and recommended dosages against established benchmarks.
Main Results:
- All analyzed cranberry CE products exhibited lower PAC content per unit than declared by manufacturers.
- Two products contained insufficient PACs even at maximum recommended daily dosage to support claimed health benefits.
- The remaining two products might offer benefits only at their highest recommended dosages, with one requiring nine capsules daily.
Conclusions:
- Significant discrepancies exist between declared and actual PAC content in cranberry CE products.
- Current dosages in many CE-marked cranberry products are inadequate for delivering promised health benefits.
- Enhanced regulatory oversight is crucial for CE-marked medicinal products to ensure consumer safety and product efficacy.
More Related Videos
12:00Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
Published on: July 5, 2017
14:39Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
Published on: April 22, 2022
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Therapeutic Index
Antihypertensive Drugs: Direct Renin Inhibitors
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cancer Prevention
Some...